The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMajedie Inv. Regulatory News (MAJE)

Share Price Information for Majedie Inv. (MAJE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 246.00
Bid: 240.00
Ask: 246.00
Change: 1.00 (0.41%)
Spread: 6.00 (2.50%)
Open: 242.00
High: 246.00
Low: 240.00
Prev. Close: 245.00
MAJE Live PriceLast checked at -
Majedie is an Investment Trust

To maximise total shareholder return whilst increasing dividends by more than the rate of inflation over the long-term by investing in securities of publicly quoted companies worldwide, though it may invest in unquoted securities.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kepler Trust Intelligence: New Research

13 Aug 2019 07:15

RNS Number : 7605I
Majedie Investments PLC
13 August 2019
 

Majedie Investments: New research

13/08/2019 Majedie Investments (MAM) offers a solid income combined with a diversified allocation to a range of funds....

Read more

Majedie Investments (MAM) aims to maximise total shareholder return while increasing dividends by more than the rate of inflation over the long term.

The portfolio is divided into six funds, all of which are managed by the well-respected boutique fund managers at Majedie Asset Management. MAM was launched in 2002 using finance provided by the investment trust and was led by a team that previously worked at Mercury Asset Management and Merrill Lynch. The strategy was to manage UK equities on behalf of institutional clients, but this has since been broadened to include global equities and an absolute return strategy, and clients now include wealth managers and endowments alongside institutions. The trust has a 17.1% stake in the privately-owned asset management company itself, which as of 31 March 2019 had £11.6bn of assets under management and makes up 27.5% of NAV (as at 30 June 2019).

The team at MAM uses a bottom up, fundamental research-based approach and a high emphasis is placed on risk aversion. When considering investments, the various investment teams look to extract the maximum return per unit of risk taken and try to understand how the holding will hold up in different market environments. As an illustration, over the past year the trust has the lowest down capture ratio, at 46.32, in the AIC Global sector, and a standard deviation of 10.86 relative to the sector average of 16.9, when excluding the effects of the holding in MAM.

Since the revamp of the trust in 2014, performance has been a tale of two halves. In the two years leading up to the 2016 European Union membership referendum, the trust delivered NAV returns of more than 50%, outperforming the MSCI World Index (49.9%), AIC Global peer group (41.7%) and the IA Global peer group (36.3%). However, the referendum result hit the trust hard, principally due to its large exposure to the UK and the cautiously positioned absolute return fund. Since then, the trust has struggled relative to global peers as investor sentiment towards Britain has soured. Over the past three years, the trust has delivered returns of 23.4% relative to 58.5% from the MSCI World, 69.4% from the AIC peer group and 52.3% from the IA peer group. With this said, the Global underlying funds have performed strongly relative to their respective benchmarks.

Alongside capital growth, dividend growth is an important part of the trust's investment proposition. The board re-set the dividend in 2014 and, since then, shareholders have seen compound progression in excess of 10% p.a. Currently, the trust is yielding 4.7%, comfortably the highest yield in the Global sector, where the weighted average is 1.3%. In fact, it is the second-highest yield of any trust in the AIC Global Equity Income sector. As of the most recent annual report, the trust retains historic revenue reserves of close to £26m.

Currently the trust is trading at a discount a little over 16%, considerably wider than the sector weighted average of 0.2%.

 Click here to read the full report

 

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Important information

Majedie Investments is a client of Kepler Trust Intelligence. This material should be considered a marketing communication, and is not independent research.

Kepler Partners is not authorised to make recommendations to Retail Clients. This report is based on factual information only, and is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

This report has been issued by Kepler Partners LLP solely for information purposes only and the views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment. If you are unclear about any of the information on this website or its suitability for you, please contact your financial or tax adviser, or an independent financial or tax adviser before making any investment or financial decisions.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. Persons who access this information are required to inform themselves and to comply with any such restrictions. In particular, this website is exclusively for non-US Persons. The information in this website is not for distribution to and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States of America to or for the benefit of US Persons.

This is a marketing document, should be considered non-independent research and is subject to the rules in COBS 12.3 relating to such research. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research.

No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not to be taken as advice to take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's conflict of interest policy is available on request.

Past performance is not necessarily a guide to the future. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that Independent financial advice should be taken before entering into any financial transaction.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is a limited liability partnership registered in England and Wales at 9/10 Savile Row, London W1S 3PF with registered number OC334771.

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority.

 

About this service

Kepler Trust Intelligence for private investors is not just another news and research website. Our aim is to create a library of high quality investment strategy research, fund analysis and useful guides for private investors, all written in-house by experienced analysts on the investment companies team at Kepler Partners.

We are focused entirely on investment trusts, however we believe that it helps to understand them better if they are placed on a level playing field with OEICs, so you will see comparisons between the two in these pages often.

 

Our content falls into three categories;

Investment strategy articles are designed to highlight opportunities and developments which are of interest to investment trust investors, positive or negative.

Fund research focuses on individual trusts, examining them in detail to create a snapshot picture which you can use to decide whether or not you want to invest in them.

Educational output is split into simple guides, designed to help beginners understand how investment trusts work, and more complex guides to sectors, regions and strategies which may be of interest to investors.

We do not produce massive amounts of research. Our focus is on quality, not quantity, so we are unlikely to publish more than four or five articles in a given week. For this reason we recommend that you join our mailing list, and we'll send you an email once a week alerting you to what's new on the site. We won't sell your details, and we won't spam you with useless updates.

 

How are we funded?

Kepler Trust Intelligence is funded entirely by the providers of investment trusts, and is made available freely to any person (professional or private individual) who wants to access it. We clearly disclose all of our relationships, but our research is either paid for directly by specific trusts and their boards, or more generally by the larger asset management groups who pay to have adverts and advertorial. As a result, all of our research should be considered "non-independent" and readers should consider it as marketing.

All of our content is freely available to anyone. We run two versions of the site - one for professionals and one for private investors. The professional site requires readers to volunteer the name of the company they work for and the city / region - so that from a compliance perspective we can be satisfied that all readers really are a professional.

 

We provide information, not advice

While we hope that you find the research we publish useful, and we believe it will help you to make a more informed decision, but we must of course stress that none of the research published here constitutes a recommendation, or advice, and you should not think that - just because we've published a report on a trust - we believe that trust is a 'buy'. Please read our terms and conditions.

 

If you want to manage your own investments we hope that this website is a useful source of information which helps you to do that, however if you are in any doubt, you should speak to a financial adviser.

 

Pascal Dowling

 

Kepler Partners

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAXLLFFKVFZBBZ
Date   Source Headline
25th Apr 20245:05 pmRNSFinal Net Asset Value
25th Apr 20245:03 pmRNSMid-Month Estimated Net Asset Value
10th Apr 20245:47 pmRNSEstimated Net Asset Value
2nd Apr 202411:27 amRNSTotal Voting Rights
25th Mar 20245:17 pmRNSHolding(s) in Company
25th Mar 20245:12 pmRNSFinal Net Asset Value
25th Mar 20245:10 pmRNSMid-Month Estimated Net Asset Value
12th Mar 202410:08 amRNSDirectorate Change
11th Mar 20245:39 pmRNSEstimated Net Asset Value
1st Mar 20242:48 pmRNSTotal Voting Rights
26th Feb 20246:15 pmRNSNet Asset Value(s)
26th Feb 20246:15 pmRNSNet Asset Value(s)
22nd Feb 20245:11 pmRNSHolding(s) in Company
1st Feb 202411:11 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSDividend Declaration
25th Jan 20245:52 pmRNSNet Asset Value(s)
25th Jan 20245:52 pmRNSNet Asset Value(s)
18th Jan 202412:46 pmRNSDirector Declaration
17th Jan 20244:17 pmRNSResult of AGM
10th Jan 202412:58 pmRNSNet Asset Value(s)
4th Jan 20242:30 pmRNSHolding(s) in Company
2nd Jan 20243:50 pmRNSResults analysis from Kepler Trust Intelligence
2nd Jan 202412:59 pmRNSTotal Voting Rights
22nd Dec 202312:42 pmRNSNet Asset Value(s)
22nd Dec 202312:41 pmRNSNet Asset Value(s)
18th Dec 20234:06 pmRNSBlock listing Interim Review
18th Dec 20237:00 amRNSAnnual Financial Report
11th Dec 20235:36 pmRNSNet Asset Value(s)
1st Dec 202311:47 amRNSTotal Voting Rights
27th Nov 20232:44 pmRNSNet Asset Value(s)
24th Nov 20235:19 pmRNSNet Asset Value(s)
17th Nov 20234:56 pmRNSHolding(s) in Company
10th Nov 20233:35 pmRNSNet Asset Value(s)
8th Nov 20237:05 amRNSBoard role change
8th Nov 20237:00 amRNSDividend Declaration
1st Nov 202310:42 amRNSTotal Voting Rights
25th Oct 20236:25 pmRNSNet Asset Value(s)
25th Oct 20236:25 pmRNSNet Asset Value(s)
10th Oct 20235:53 pmRNSNet Asset Value(s)
2nd Oct 202311:32 amRNSTotal Voting Rights
25th Sep 20235:14 pmRNSNet Asset Value(s)
25th Sep 20235:13 pmRNSNet Asset Value(s)
11th Sep 20235:45 pmRNSNet Asset Value(s)
1st Sep 202311:42 amRNSTotal Voting Rights
30th Aug 202312:59 pmRNSHolding(s) in Company
25th Aug 202312:59 pmRNSNet Asset Value(s)
25th Aug 202312:58 pmRNSNet Asset Value(s)
10th Aug 20236:13 pmRNSNet Asset Value(s)
2nd Aug 20237:00 amRNSDividend Declaration
1st Aug 20234:12 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.